A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a
A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.
대표청구항▼
1. A method of preparing a multi-drug eluting coronary stent comprising: a. providing a stent framework;b. depositing on said stent framework a first layer comprising a first pharmaceutical agent in dry powder form without use of a solvent;c. depositing a second layer in dry powder form without use
1. A method of preparing a multi-drug eluting coronary stent comprising: a. providing a stent framework;b. depositing on said stent framework a first layer comprising a first pharmaceutical agent in dry powder form without use of a solvent;c. depositing a second layer in dry powder form without use of a solvent, the second layer comprising a second pharmaceutical agent;d. depositing one or more polymer layers thereby forming a coating; and thene. sintering said coating under conditions that do not substantially modify a morphology of said pharmaceutical agents, wherein said sintering comprises treating the coated stent framework with a compressed gas, compressed liquid, or super critical fluid that is a non-solvent for both the polymer and pharmaceutical agents;wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents and at least one of said first and second pharmaceutical agents comprises the morphology that is crystalline or semi-crystalline. 2. The method of claim 1, wherein at least one of said polymer layers comprises a bioabsorbable polymer. 3. The method of claim 1 wherein said polymer is selected from PLA, PLGA, PGA and Poly(dioxanone). 4. The method of claim 1 comprising depositing 5 or more layers as follows: a first polymer layerthe first layer comprising said first pharmaceutical agenta second polymer layerthe second layer comprising said second pharmaceutical agent; anda third polymer layer. 5. The method of claim 1 comprising depositing 4 or more layers as follows: a first polymer layerthe first layer comprising said first pharmaceutical agenta second polymer layer; andthe second layer comprising said second pharmaceutical agent. 6. The method of claim 1 comprising depositing 4 or more layers as follows: the first layer comprising said first pharmaceutical agenta first polymer layerthe second layer comprising said second pharmaceutical agent; anda second polymer layer. 7. The method of Claim 1 comprising depositing 3 or more layers as follows: the first layer comprising said first pharmaceutical agenta polymer layer; andthe second layer comprising said second pharmaceutical agent. 8. The method of claim 1 wherein said layers comprise alternate layers of pharmaceutical agent, or pharmaceutical agent and polymer, and layers of polymer without pharmaceutical agent. 9. The method of claim 8, wherein the pharmaceutical agent layers are substantially free of polymer and the polymer layers are substantially free of pharmaceutical agent. 10. The method of claim 1 comprising depositing 5, 10, 20, 50, or 100 layers. 11. The method of claim 1 wherein said first pharmaceutical agent has an elution profile that is slower than the elution profile of the second pharmaceutical agent. 12. The method of claim 11 wherein the second pharmaceutical agent achieves 100% elution in about 5 days to about 20 days and the first pharmaceutical agent achieves 100% elution in about 120 days to about 180 days. 13. The method of claim 1, wherein said first pharmaceutical agent is anti-thrombogenic agent and said second pharmaceutical agent is an anti-restenotic agent. 14. The method of claim 1, wherein said first pharmaceutical agent is heparin and said second pharmaceutical agent is taxol or a macrolide immunosuppressive (limus) drug. 15. The method of claim 2, wherein said bioabsorbable polymer is selected from PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone)PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPLG, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly (1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid). 16. The method of claim 1, wherein at least one of said pharmaceutical agents comprise a macrolide immunosuppressive (limus) drug. 17. The method of claim 16, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), and 40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus). 18. The method of claim 16, wherein said macrolide immunosuppressive drug is at least 50% crystalline. 19. The method of claim 1, comprising depositing polymer particles on said framework by an RESS process. 20. The method of claim 1, comprising depositing pharmaceutical agent particles on said framework in dry powder form. 21. A multi-drug eluting coronary stent prepared by the method of claim 1. 22. A multi-drug coronary stent comprising a. a stent framework;b. a first layer comprising a first pharmaceutical agent;c. a second layer comprising a second pharmaceutical agent; andd. one or more polymer layers thereby forming a coating;wherein said coating is sintered under conditions that do not substantially modify the morphology of said pharmaceutical agents, wherein said sintering comprises treating the coated stent framework with a compressed gas, compressed liquid, or super critical fluid that is a non-solvent for both the polymer and pharmaceutical agents;wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents and at least one of said first and second pharmaceutical agents are crystalline or semi-crystalline; and wherein the stent has no residual solvent. 23. The stent of claim 22, wherein at least one of said polymer layers comprises a bioabsorbable polymer. 24. The stent of claim 22 wherein said polymer is selected from PLA, PLGA, PGA and Poly(dioxanone). 25. The stent of claim 22 comprising 5 or more layers as follows: a first polymer layerthe first layer comprising said first pharmaceutical agenta second polymer layerthe second layer comprising said second pharmaceutical agent; anda third polymer layer. 26. The stent of claim 22 comprising 4 or more layers as follows: a first polymer layerthe first layer comprising said first pharmaceutical agenta second polymer layer; andthe second layer comprising said second pharmaceutical agent. 27. The stent of claim 22 comprising 4 or more layers as follows: the first layer comprising said first pharmaceutical agenta first polymer layerthe second layer comprising said second pharmaceutical agent; anda second polymer layer. 28. The stent of claim 22 comprising 3 or more layers as follows: the first layer comprising said first pharmaceutical agenta polymer layer; andthe second layer comprising said second pharmaceutical agent. 29. The stent of claim 22 wherein said layers comprise alternate layers of pharmaceutical agent, or pharmaceutical agent and polymer, and layers of polymer without pharmaceutical agent. 30. The stent of claim 28, wherein the pharmaceutical agent layers are substantially free of polymer and the polymer layers are substantially free of pharmaceutical agent. 31. The stent of claim 22 comprising depositing 5, 10, 20, 50, or 100 layers. 32. The stent of claim 22 wherein said first pharmaceutical agent has an elution profile that is slower than the elution profile of the second pharmaceutical agent. 33. The stent of claim 32 wherein the second pharmaceutical agent achieves 100% elution in about 5 days to about 20 days and the first pharmaceutical agent achieves 100% elution in about 120 days to about 180 days. 34. The stent of claim 22, wherein said first pharmaceutical agent is anti-thrombogenic agent and said second pharmaceutical agent is an anti-restenotic agent. 35. The stent of claim 22, wherein said first pharmaceutical agent is heparin and said second agent is taxol or a macrolide immunosuppressive (limus) drug. 36. The stent of claim 23, wherein said bioabsorbable polymer is selected from PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPLG, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid). 37. The stent of claim 22, wherein at least one of said pharmaceutical agents comprise a macrolide immunosuppressive (limus) drug. 38. The method of claim 37, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin,40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-(2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R) -26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), and 40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (162)
Fenster, Aaron; Downey, Donal B., 3D ultrasound-guided intraoperative prostate brachytherapy.
Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Liu Cheng-Kung (Norwalk CT), Absorbable block copolymers and surgical articles fabricated therefrom.
Wang James C. (Norton) Roberts George R. (Arlington) Pederson ; Sr. Brian A. (So. Attleboro MA), Co-extruded medical balloons and catheter using such balloons.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent.
Liu Cheng-Kung (Norwalk CT) Jiang Ying (North Haven CT) Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Stevenson Richard P. (Colchester CT) Pietrangeli Jeffrey P. (Bridgeport CT), Composite bioabsorbable materials and surgical articles made therefrom.
Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel, Composition for treating vascular diseases characterized by nitric oxide insufficiency.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Merida A. D'Augustine ; James H. Liu ; Donald C. Harrison, Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections.
Burke,Sandra E.; Cromack,Keith R.; Mack,Matthew; Toner,John L., Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens.
Hoy Kenneth L. (St. Albans WV) Nielsen Kenneth A. (Charleston WV), Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice.
Palmaz, Julio C.; Boyle, Christopher T.; Banas, Christopher E.; Wiseman, Roger W.; Marton, Denes, Endoluminal implantable devices and method of making same.
Francis Moussy ; Donald Kreutzer ; Diane Burgess ; Jeffrey Koberstein ; Fotios Papadimitrakopoulos ; Samuel Huang, Implant coating for control of tissue/implant interactions.
Yoon Seok-Joon,KRX ; Yeo Guw-Dong,KRX ; Kim You-Chan,KRX ; Seo Min-Hyo,KRX ; Pai Chaul-Min,KRX ; Jung Jong-Pyoung,KRX ; Lee Seung-Jin,KRX, Implantable bioresorbable membrane and method for the preparation thereof.
Canham, Leigh T; Barrett, Christopher P; Cox, Timothy I; Wright, Peter J; Bowditch, Andrew P, Implants for administering substances and methods of producing implants.
Mistrater Alan B. (Rochester NY) Pietrzykowski ; Jr. Stanley J. (Rochester NY) Klein Alfred O. (Rochester NY) Hendrix Loren E. (Webster NY) Petropoulos Mark C. (Ontario NY) Batt Gary A. (Fairport NY), Mandrel with flared, dish shaped disk and process for using mandrel.
Pletcher Timothy Allen ; Datta Pabitra ; Poux Christopher Just ; McCoy Randall Eugene, Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate.
Burnham, Theodore A.; Cha, Sung W.; Walat, Robert H.; Kim, Roland Y.; Anderson, Jere R.; Stevenson, James F.; Suh, Nam P.; Pallaver, Matthew, Method and apparatus for microcellular polymer extrusion.
Lars Lidgren SE; Peter Bengtsson SE; Peter Sj{overscore (o)}vall SE; Bengt Wesslen SE, Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof.
Luzzi Louis A. ; Needham Thomas E. ; Hossein Zia ; Dondeti Polireddy, Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa.
Anderson Jere R. (Newburyport MA) Jandris Louis J. (Georgetown MA) Barbere Michael D. (Dunstable MA) Murphy Richard T. (Dracut MA 4), Method of making a distensible dilatation balloon using a block copolymer.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
DeYoung, James P.; Gross, Stephen M.; Wagner, Mark I.; McClain, James B., Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide.
Roser, Bruce J.; Sanderson, Ian; Kampinga, Jaap; Colaco, Camilo, Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery.
D'Amato, Robert J.; Green, Shawn J.; Swartz, Jr., Glenn M.; Shah, Jamshed H.; Madsen, John, Methods and compositions for treating an ocular neovascular disease.
DeYoung, James P.; McClain, James B.; Gross, Stephen M.; Wagner, Mark I., Methods for transferring supercritical fluids in microelectronic and other industrial processes.
Cha Sung W. (Cambridge MA) Suh Nam P. (Sudbury MA) Baldwin Daniel F. (Medford MA) Park Chul B. (Cambridge MA), Microcellular thermoplastic foamed with supercritical fluid.
Tepper, Gary; Pestov, Dmitry; Levit, Natalia; Wnek, Gary, Molecular imprinting of small particles, and production of small particles from solid state reactants.
Beckert, Thomas; Petereit, Hans-Ulrich; Dressman, Jennifer; Rudolph, Markus, Multi-particulate form of medicament, comprising at least two differently coated forms of pellet.
Maxfield MacRae (Plainfield NJ) Christiani Brian R. (Maplewood NJ) Murthy Sanjeeva N. (Neshanic Station NJ) Tuller Harold (Long Valley NJ), Nanocomposites of gamma phase polymers containing inorganic particulate material.
Cecchi, Roberto; Croci, Tiziano; Guzzi, Umberto; Marsault, Eric, Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same.
Raeder-Devens, Jennifer E.; Shelso, Susan I.; Hemerick, James F.; Schneider, Eric M.; Getty, Heather L.; Borgmann, Doreen M.; Sisombath, Kakao; Helgerson, Jeffrey A., Prosthesis deployment device with translucent distal end.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Lafont Antoine,FRX ; Vert Michel R.,FRX ; Cornhill Fredrick ; Li Suming,FRX ; Garreau Henri L.,FRX, Stent having a programmed pattern of in vivo degradation.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Tsukashima Ross (San Diego CA) Jordan Matthew (Los Angeles CA) Jung Gordon (San Diego CA), Tri-fold balloon for dilatation catheter and related method.
Rodrigues Jose,FRX ; Belmain Daniel,FRX ; Barlet Thierry,FRX, Triboelectric projector, installation for projecting coating product and process for controlling such a projector.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.